BBS-1 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human BBS1 (UniProt Q8NFJ9), full-length 593 aa, expressed in HEK293 cells. Core BBSome complex subunit used in ciliary trafficking studies, protein–protein interaction assays, and antibody validation.
Expression system
HEK293
Cat. #
REC-BBS1

In stock

SKU
REC-BBS1
$498.00

Target Overview

BBS1 (BBSome complex member BBS1; UniProt Q8NFJ9) is a 593-amino-acid scaffold subunit of the BBSome, an octameric coat-like complex that sorts specific membrane proteins to the primary cilium. This recombinant form is expressed in HEK293 mammalian cells, preserving the post-translational modifications and folding characteristic of the human protein — an important consideration for a protein whose function depends on tight assembly with seven other BBSome subunits and on regulated interactions with ciliary membrane components. The recombinant protein spans the full 593-residue sequence (UniProt Q8NFJ9), making it suitable as a positive control antigen, a binding partner in pull-down or co-immunoprecipitation experiments, and a reference standard in structural or biophysical characterisation workflows. In the context of BBSome assembly research, recombinant BBS1 has been used to probe interactions with RAB3IP/Rabin8 — the guanosyl exchange factor for Rab8 — and with other BBSome subunits whose architecture has been investigated through computational structural modelling (Guo DF et al., 2026, PMID: 41915029). Researchers validating anti-BBS1 antibodies against a defined, species-matched antigen will find this HEK293-expressed recombinant preferable to prokaryotic preparations, because eukaryotic expression supports correct disulfide bonding and glycosylation patterns absent from E. coli systems. For antibody validation workflows, this recombinant pairs directly with the matched Triple Point Biologics anti-BBS1 antibody (SKU: RP-BBS1), which has been validated for Western blot against human samples. HEK293 expression also makes this reagent well-suited to interaction studies where conformational integrity of the folded domain is required for meaningful binding data.

Background

BBS1 encodes the founding scaffold subunit of the BBSome, an evolutionarily conserved octameric complex that functions as a coat assembly for the primary cilium membrane. The BBSome is required for ciliogenesis and for the selective trafficking of G protein-coupled receptors and other signalling proteins into and out of cilia. BBS1 is essential for correct BBSome assembly and for the complex's localisation to the cilium: without BBS1, the entire complex fails to associate with the ciliary membrane. Mechanistically, the BBSome recruits RAB3IP/Rabin8 to the basal body; Rabin8 then activates Rab8, which in its GTP-bound state promotes docking and fusion of carrier vesicles at the base of the ciliary membrane, thereby extending the ciliary compartment. The BBSome also cooperates with LTZL1 to control Smoothened (SMO) trafficking within cilia, connecting the complex to regulation of the Sonic Hedgehog (SHH) signalling pathway. In human genetics, loss-of-function variants in BBS1 are among the most commonly identified causes of Bardet-Biedl syndrome (BBS), a pleiotropic ciliopathy characterised by retinal dystrophy, obesity, polydactyly, renal anomalies, and cognitive differences. BBS1 variants account for a substantial proportion of genetically confirmed BBS cases; a large clinical cohort study confirmed BBS1 as one of the highest-frequency BBS loci (Demir Ş et al., 2025, PMID: 41219488). As a research target, BBS1 is studied to dissect how ciliary trafficking defects translate into the distinct tissue pathologies observed in ciliopathies. Beyond structural ciliogenesis, BBS1 has been investigated in the context of broader signalling crosstalk. Phosphoproteomic profiling in BBS1 knockout cellular models identified CDC42 and CDK2 as kinase nodes regulated downstream of BBS1 loss, with effects on the TGF-β pathway — underscoring that BBS1 research extends into proliferative and fibrotic signalling contexts (Bea-Mascato B et al., 2025, PMID: 41193622). Computational structural approaches using AlphaFold3 have also been applied to map BBSome architecture and define BBS1 protein–protein interaction interfaces at atomic resolution (Guo DF et al., 2026, PMID: 41915029), providing a structural framework that guides the design of biochemical binding and competition assays using recombinant BBS1 protein.

Applications

  • Positive control antigen in Western blot validation of anti-BBS1 antibodies (pair with SKU RP-BBS1)
  • Binding partner in pull-down or co-immunoprecipitation assays to map BBSome subunit interactions
  • Reference standard in surface plasmon resonance (SPR) or biolayer interferometry (BLI) binding kinetics experiments with RAB3IP/Rabin8 or other BBSome partners
  • Antigen spike-in for ELISA sensitivity and standard-curve calibration in BBS1 detection assays
  • Structural and biophysical characterisation (SEC-MALS, native PAGE) of BBSome subunit folding and complex formation
  • Phosphoproteomic or signalling pathway studies using recombinant BBS1 as a defined substrate or interaction bait in cell-free systems
  • IHC antibody titration control: use as a spotted antigen on nitrocellulose to establish antibody working concentrations before tissue staining

References

  1. Guo DF et al. Harnessing AlphaFold3 to elucidate BBSome structure and protein partners. Am J Physiol Cell Physiol. 2026. doi: 10.1152/ajpcell.00804.2025. PMID: 41915029.
  2. Bea-Mascato B et al. Phosphoproteomic profiling highlights CDC42 and CDK2 as key players in the regulation of the TGF-β pathway in ALMS1 and BBS1 knockout models. Sci Rep. 2025. doi: 10.1038/s41598-025-22584-0. PMID: 41193622.
  3. Demir Ş et al. Comprehensive clinical and genetic characterization of Bardet-Biedl Syndrome: insights from the largest Turkish cohort. Eur J Pediatr. 2025. doi: 10.1007/s00431-025-06592-w. PMID: 41219488.
  4. Kiattiubolwong T et al. Genetic determinants of drug-induced gingival overgrowth. Sci Rep. 2026. doi: 10.1038/s41598-026-52779-y. PMID: 42156840.
  5. Botthoulath V et al. Genomic Analysis for the Safety Assessment of a Potential Probiotic Strain Pediococcus pentosaceus BBS1 Isolated From Lao Fermented Bamboo Shoots (Nor Mai Som). Microbiologyopen. 2025. doi: 10.1002/mbo3.70048. PMID: 40923755.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Subcellular localization not yet annotated

Frequently Asked Questions

What is the expected molecular weight of recombinant BBS1 on SDS-PAGE and Western blot?

Recombinant BBS1 (REC-BBS1) spans the full 593-residue sequence of human BBS1 (UniProt Q8NFJ9), giving a predicted molecular weight of approximately 67 kDa. On denaturing SDS-PAGE, the band typically migrates at 68–72 kDa — a slight upward shift attributable to post-translational modifications retained from the HEK293 expression system. Purity is >90% by SDS-PAGE. If your Western blot shows a diffuse band or doublet near 70 kDa, this is consistent with phosphorylation or other PTMs and is not indicative of degradation.

Does recombinant BBS1 undergo any post-translational processing or exist as multiple isoforms?

The canonical human BBS1 sequence (UniProt Q8NFJ9, isoform 1) is the basis for REC-BBS1 — no truncation or alternative splicing is introduced. Because expression is in HEK293 mammalian cells, the protein carries human-relevant phosphorylation and glycosylation that a bacterial or insect-cell system would not reproduce. No known proteolytic cleavage event converts BBS1 to a shorter processed form under physiological conditions. The intact 593-residue protein is the biologically relevant assembly-competent form for BBSome co-complex studies.

What protein interactions can I study with recombinant BBS1 in pull-down or co-IP experiments?

REC-BBS1 is well-suited as bait or prey in pull-down assays interrogating BBSome assembly. Published work has used recombinant BBS1 to probe direct binding to RAB3IP/Rabin8 — the guanine nucleotide exchange factor for Rab8a — and to other BBSome subunits (BBS2, BBS7, BBS9). For pull-down, we recommend using REC-BBS1 at 1–5 µg per reaction in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — the native storage buffer — supplemented with 0.1% NP-40 to reduce non-specific binding. Confirm pulled complexes by Western blot using the matched antibody RP-BBS1.

What buffer conditions are optimal for recombinant BBS1 binding assays or biophysical characterisation?

REC-BBS1 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — a buffer chosen to maintain solubility and the native fold of the assembled scaffold domain. For SPR or ITC experiments, dialysing into a matched running buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 0.005% Tween-20) at 4°C overnight is advisable. Avoid buffers below pH 6.5 or above pH 8.5, and keep glycerol at ≥5% if diluting significantly, as BBS1 has a tendency to aggregate at low ionic strength without a stabilising co-solute.

Is recombinant BBS1 an enzyme — does it have catalytic activity, and is there a standard activity assay?

BBS1 is a structural scaffold subunit of the BBSome coat complex, not a catalytic enzyme. It does not possess intrinsic ATPase, GTPase, kinase, or protease activity. Consequently, there is no standard small-molecule substrate activity assay for BBS1 in isolation. Functional characterisation is typically assessed by complex reconstitution (co-sedimentation or SEC-based assembly assays with other BBSome subunits) or by binding affinity measurements against partners such as RAB3IP/Rabin8. REC-BBS1 is therefore most appropriate as a positive control antigen, structural bait, or reference protein rather than an enzymatically active reagent.

How much recombinant BBS1 should I load as a positive control on a Western blot with the RP-BBS1 antibody?

For Western blot positive controls using the matched antibody RP-BBS1 (/anti-bbs-1-rabbit-polyclonal-antibody), load 10–50 ng of REC-BBS1 per lane. At 50 ng you should see a clean, strong band at approximately 68–72 kDa with standard ECL detection. If you are titrating alongside cell lysate, start at 20 ng to avoid overexposure relative to endogenous signal. RP-BBS1 is guaranteed compatible with REC-BBS1 for Western blot — both originate from the same TPB development pipeline — so band identity is unambiguous when run in parallel.

Can I use REC-BBS1 to validate the RP-BBS1 rabbit polyclonal antibody for Western blot or IHC?

Yes — this is one of the primary use cases for REC-BBS1. Because RP-BBS1 was raised and quality-controlled against the same full-length human BBS1 sequence represented by REC-BBS1, the recombinant is a reliable positive control antigen for Western blot validation. For antibody titration, run 25–100 ng REC-BBS1 alongside your lysate of interest and titrate RP-BBS1 from 1:500 to 1:5000. For IHC validation workflows requiring soluble antigen spiking or dot-blot confirmation, REC-BBS1 at 100–500 ng provides a clean signal at the expected molecular weight without background from endogenous proteins.

How should I store and handle recombinant BBS1 to maintain activity and avoid degradation?

REC-BBS1 is shipped on dry ice and should be stored at -20°C immediately upon receipt. The supplied buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — stabilises the protein during freeze-thaw, but repeated cycling degrades both solubility and binding competence. Aliquot into single-use volumes before the first freeze. Working dilutions in assay buffer can be held at 4°C for up to 48 hours; do not leave the protein at room temperature for extended periods. Endotoxin is <0.1 EU/µg by LAL assay, so REC-BBS1 is suitable for cell-based experiments where LPS contamination would confound results.

Validation imagery coming soon

Western blot validation figures for REC-BBS1 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →